Prospective evaluation of risk-appropriate management of uveal melanoma patients informed by gene expression profiling

Melanoma Management

Scott C N Oliver¹  Amy C Schefler²  Alison Skalet³  John Mason⁴  Anthony B Daniels⁵  Katherina M Alsina⁶  Federico A Monzon⁷  Brian Firestone⁷  Kristen M Plasseraud⁷ 

[1] Science University, Portland, OR 97239, USA;1Retina Consultants of Houston, Houston, TX 77030, USA;;2Dept. of Ophthalmology, Casey Eye Institute, Oregon Health &3Sue Anschutz-Rogers Eye Center, University of Colorado, Aurora, CO 80045, USA;4Retina Consultants of Alabama, Birmingham, AL 35233, USA;5Dept. of Ophthalmology and Visual Sciences, Vanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville, TN 37232, USA;6Castle Biosciences, Inc., Friendswood, TX 77546, USA;

关键词: DecisionDx-UM;    gene expression profiling;    imaging;    ocular melanoma;    surveillance;    uveal melanoma;   

DOI  :  10.2217/mmt-2020-0001

来源: DOAJ

【 摘 要 】

Aim: The Clinical Application of DecisionDx-UM Gene Expression Assay Results study aimed to evaluate the clinical utility of the prognostic 15-gene expression profile (15-GEP) test for uveal melanoma (UM) patients in a large, prospective multicenter cohort. Patients & methods: Nine centers prospectively enrolled 138 UM patients clinically tested with the 15-GEP. Physician-recommended specialty referrals and metastatic surveillance regimens were collected. Results: A total of 93% of high-risk class 2 patients were referred to medical oncology for follow-up, compared with 51% of class 1 patients. A majority (62%) of class 2 patients were recommended overall high-intensity metastatic surveillance, while 85% of class 1 patients were recommended low-intensity metastatic surveillance. Conclusion: Treatment plan recommendations for UM patients are aligned with GEP-informed metastatic risk, consistent with prior studies.

【 授权许可】

Unknown